SCHEMBL10165643

SCHEMBL10165643

CC(=O)c1cc(C(=O)NCc2ccc(F)c(C)c2)nc2ccnn12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 10/20 0.58
MMP8 P22894 4/20 0.48
MMP10 P09238 3/20 0.48
MMP9 P14780 1/20 0.48
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
ADAMTS4 O75173 1/20 0.40
MMP3 P08254 1/20 0.40
MMP12 P39900 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PPARG P37231 1/20 0.39
CACNA1G O43497 1/20 0.39
CACNA1H O95180 1/20 0.39
CACNA1I Q9P0X4 1/20 0.39
WDR5 P61964 1/20 0.39
PDE10A Q9Y233 1/20 0.39
MAPK13 O15264 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK11 Q15759 1/20 0.38
MAPK14 Q16539 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8258270 0.94 MMP13 (0.61) MMP13MMP8MMP10MMP9HCRTR1
SCHEMBL8185116 0.92 MMP13 (0.58) MMP13MMP8MMP10MMP9HCRTR1
SCHEMBL10165651 0.92 MMP13 (0.46) MMP13MMP8ADAMTS4MMP3MMP12
SCHEMBL10162464 0.91 MMP13 (0.53) MMP13MMP8MMP10MMP9HCRTR1
SCHEMBL10162426 0.91 MMP13 (0.53) MMP13MMP8MMP10MMP9HCRTR1
SCHEMBL8185121 0.90 MMP13 (0.56) MMP13MMP8MMP10MMP9HCRTR1
SCHEMBL10165461 0.89 MAPK1 (0.46) MMP13PPARGWDR5
SCHEMBL14449876 0.87 MMP13 (0.58) MMP13MMP8MMP10MMP9ADAMTS4
SCHEMBL10162336 0.87 MMP13 (0.49) MMP13MMP8MMP10MMP9HCRTR1
SCHEMBL10162301 0.86 MMP13 (0.53) MMP13MMP8MMP10MMP9HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885MMP8 26/4885MMP10 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.